---
document_datetime: 2025-12-29 08:15:20
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/zelnorm.html
document_name: zelnorm.html
version: success
processing_time: 0.0585298
conversion_datetime: 2025-12-30 03:22:51.375007
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Zelnorm

[RSS](/en/individual-human-medicine.xml/66789)

##### Refused

This medicine has been refused authorisation

tegaserod Medicine Human Refused

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product details](#product-details)
- [Application details](#authorisation-details)
- [Assessment history](#assessment-history)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 15 December 2005 the Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion, recommending the refusal of the marketing authorisation for the medicinal product Zelnorm 6 mg tablets.

Following request from the applicant, the CHMP re-examined the opinion and confirmed its previous view on 23 March 2006.

Zelnorm aims to relieve the symptoms of irritable bowel syndrome with constipation in women. Zelnorm is approved outside the European Union for the treatment of irritable bowel syndrome and chronic constipation. The company who applied is Novartis Europharm Limited.

Questions and answers on the recommendation for the refusal of the marketing authorisation for Zelnorm

Reference Number: EMEA/CHMP/109088/2006

English (EN) (30.01 KB - PDF)

**First published:** 23/10/2007

**Last updated:** 23/10/2007

[View](/en/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-zelnorm_en.pdf)

[Other languages (18)](#file-language-dropdown-325)

español (ES) (33.24 KB - PDF)

**First published:**

23/10/2007

**Last updated:**

23/10/2007

[View](/es/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-zelnorm_es.pdf)

čeština (CS) (118.49 KB - PDF)

**First published:**

23/10/2007

**Last updated:**

23/10/2007

[View](/cs/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-zelnorm_cs.pdf)

dansk (DA) (33.1 KB - PDF)

**First published:**

23/10/2007

**Last updated:**

23/10/2007

[View](/da/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-zelnorm_da.pdf)

Deutsch (DE) (33.54 KB - PDF)

**First published:**

23/10/2007

**Last updated:**

23/10/2007

[View](/de/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-zelnorm_de.pdf)

eesti keel (ET) (33.29 KB - PDF)

**First published:**

23/10/2007

**Last updated:**

23/10/2007

[View](/et/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-zelnorm_et.pdf)

ελληνικά (EL) (157.37 KB - PDF)

**First published:**

23/10/2007

**Last updated:**

23/10/2007

[View](/el/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-zelnorm_el.pdf)

français (FR) (33.44 KB - PDF)

**First published:**

23/10/2007

**Last updated:**

23/10/2007

[View](/fr/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-zelnorm_fr.pdf)

italiano (IT) (33.11 KB - PDF)

**First published:**

23/10/2007

**Last updated:**

23/10/2007

[View](/it/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-zelnorm_it.pdf)

latviešu valoda (LV) (118.92 KB - PDF)

**First published:**

23/10/2007

**Last updated:**

23/10/2007

[View](/lv/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-zelnorm_lv.pdf)

lietuvių kalba (LT) (116.6 KB - PDF)

**First published:**

23/10/2007

**Last updated:**

23/10/2007

[View](/lt/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-zelnorm_lt.pdf)

magyar (HU) (111.94 KB - PDF)

**First published:**

23/10/2007

**Last updated:**

23/10/2007

[View](/hu/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-zelnorm_hu.pdf)

Nederlands (NL) (33.23 KB - PDF)

**First published:**

23/10/2007

**Last updated:**

23/10/2007

[View](/nl/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-zelnorm_nl.pdf)

polski (PL) (120.93 KB - PDF)

**First published:**

23/10/2007

**Last updated:**

23/10/2007

[View](/pl/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-zelnorm_pl.pdf)

português (PT) (33.25 KB - PDF)

**First published:**

23/10/2007

**Last updated:**

23/10/2007

[View](/pt/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-zelnorm_pt.pdf)

slovenčina (SK) (115.73 KB - PDF)

**First published:**

23/10/2007

**Last updated:**

23/10/2007

[View](/sk/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-zelnorm_sk.pdf)

slovenščina (SL) (108.17 KB - PDF)

**First published:**

23/10/2007

**Last updated:**

23/10/2007

[View](/sl/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-zelnorm_sl.pdf)

Suomi (FI) (32.96 KB - PDF)

**First published:**

23/10/2007

**Last updated:**

23/10/2007

[View](/fi/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-zelnorm_fi.pdf)

svenska (SV) (33.04 KB - PDF)

**First published:**

23/10/2007

**Last updated:**

23/10/2007

[View](/sv/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-zelnorm_sv.pdf)

## Product details

Name of medicine Zelnorm Active substance tegaserod International non-proprietary name (INN) or common name tegaserod Therapeutic area (MeSH) Irritable Bowel Syndrome Anatomical therapeutic chemical (ATC) code A03AE02

### Pharmacotherapeutic group

Drugs for functional gastrointestinal disorders

## Application details

EMA product number EMEA/H/C/000621 Marketing authorisation applicant Novartis Europharm Limited Opinion adopted 23/03/2006 Refusal of marketing authorisation 19/05/2006

## Assessment history

Zelnorm : EPAR - Refusal public assessment report

English (EN) (310.77 KB - PDF)

**First published:** 22/10/2007

**Last updated:** 22/10/2007

[View](/en/documents/assessment-report/zelnorm-epar-refusal-public-assessment-report_en.pdf)

**This page was last updated on** 31/12/2009

## Share this page

[Back to top](#main-content)